12/31false2025Q30001808220xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesgoco:stategoco:employeexbrli:puregoco:votegoco:daygoco:leasegoco:segment00018082202025-01-012025-09-300001808220us-gaap:CommonClassAMember2025-11-060001808220us-gaap:CommonClassBMember2025-11-0600018082202025-07-012025-09-3000018082202024-07-012024-09-3000018082202024-01-012024-09-3000018082202025-09-3000018082202024-12-310001808220us-gaap:RedeemableConvertiblePreferredStockMember2024-12-310001808220us-gaap:RedeemableConvertiblePreferredStockMember2025-09-300001808220us-gaap:CommonClassAMember2025-09-300001808220us-gaap:CommonClassAMember2024-12-310001808220us-gaap:CommonClassBMember2025-09-300001808220us-gaap:CommonClassBMember2024-12-310001808220us-gaap:ConvertiblePreferredStockMember2025-09-300001808220us-gaap:ConvertiblePreferredStockMember2024-12-310001808220us-gaap:CommonClassAMemberus-gaap:CommonStockMember2025-06-300001808220us-gaap:CommonClassBMemberus-gaap:CommonStockMember2025-06-300001808220us-gaap:CommonClassAMemberus-gaap:TreasuryStockCommonMember2025-06-300001808220us-gaap:AdditionalPaidInCapitalMember2025-06-300001808220us-gaap:RetainedEarningsMember2025-06-300001808220us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-06-300001808220us-gaap:NoncontrollingInterestMember2025-06-3000018082202025-06-300001808220us-gaap:RetainedEarningsMember2025-07-012025-09-300001808220us-gaap:NoncontrollingInterestMember2025-07-012025-09-300001808220us-gaap:CommonClassAMemberus-gaap:CommonStockMember2025-07-012025-09-300001808220us-gaap:AdditionalPaidInCapitalMember2025-07-012025-09-300001808220us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-07-012025-09-300001808220us-gaap:CommonClassAMemberus-gaap:TreasuryStockCommonMember2025-07-012025-09-300001808220us-gaap:CommonClassBMemberus-gaap:CommonStockMember2025-07-012025-09-300001808220us-gaap:CommonClassAMemberus-gaap:CommonStockMember2025-09-300001808220us-gaap:CommonClassBMemberus-gaap:CommonStockMember2025-09-300001808220us-gaap:CommonClassAMemberus-gaap:TreasuryStockCommonMember2025-09-300001808220us-gaap:AdditionalPaidInCapitalMember2025-09-300001808220us-gaap:RetainedEarningsMember2025-09-300001808220us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-09-300001808220us-gaap:NoncontrollingInterestMember2025-09-300001808220us-gaap:CommonClassAMemberus-gaap:CommonStockMember2024-06-300001808220us-gaap:CommonClassBMemberus-gaap:CommonStockMember2024-06-300001808220us-gaap:CommonClassAMemberus-gaap:TreasuryStockCommonMember2024-06-300001808220us-gaap:AdditionalPaidInCapitalMember2024-06-300001808220us-gaap:RetainedEarningsMember2024-06-300001808220us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300001808220us-gaap:NoncontrollingInterestMember2024-06-3000018082202024-06-300001808220us-gaap:RetainedEarningsMember2024-07-012024-09-300001808220us-gaap:NoncontrollingInterestMember2024-07-012024-09-300001808220us-gaap:CommonClassAMemberus-gaap:CommonStockMember2024-07-012024-09-300001808220us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300001808220us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300001808220us-gaap:CommonClassAMemberus-gaap:TreasuryStockCommonMember2024-07-012024-09-300001808220us-gaap:CommonClassBMemberus-gaap:CommonStockMember2024-07-012024-09-300001808220us-gaap:CommonClassAMemberus-gaap:CommonStockMember2024-09-300001808220us-gaap:CommonClassBMemberus-gaap:CommonStockMember2024-09-300001808220us-gaap:CommonClassAMemberus-gaap:TreasuryStockCommonMember2024-09-300001808220us-gaap:AdditionalPaidInCapitalMember2024-09-300001808220us-gaap:RetainedEarningsMember2024-09-300001808220us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-300001808220us-gaap:NoncontrollingInterestMember2024-09-3000018082202024-09-300001808220us-gaap:CommonClassAMemberus-gaap:CommonStockMember2024-12-310001808220us-gaap:CommonClassBMemberus-gaap:CommonStockMember2024-12-310001808220us-gaap:CommonClassAMemberus-gaap:TreasuryStockCommonMember2024-12-310001808220us-gaap:AdditionalPaidInCapitalMember2024-12-310001808220us-gaap:RetainedEarningsMember2024-12-310001808220us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310001808220us-gaap:NoncontrollingInterestMember2024-12-310001808220us-gaap:RetainedEarningsMember2025-01-012025-09-300001808220us-gaap:NoncontrollingInterestMember2025-01-012025-09-300001808220us-gaap:CommonClassAMemberus-gaap:CommonStockMember2025-01-012025-09-300001808220us-gaap:AdditionalPaidInCapitalMember2025-01-012025-09-300001808220us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-09-300001808220us-gaap:CommonClassAMemberus-gaap:TreasuryStockCommonMember2025-01-012025-09-300001808220us-gaap:CommonClassBMemberus-gaap:CommonStockMember2025-01-012025-09-300001808220us-gaap:CommonClassAMemberus-gaap:CommonStockMember2023-12-310001808220us-gaap:CommonClassBMemberus-gaap:CommonStockMember2023-12-310001808220us-gaap:CommonClassAMemberus-gaap:TreasuryStockCommonMember2023-12-310001808220us-gaap:AdditionalPaidInCapitalMember2023-12-310001808220us-gaap:RetainedEarningsMember2023-12-310001808220us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001808220us-gaap:NoncontrollingInterestMember2023-12-3100018082202023-12-310001808220us-gaap:RetainedEarningsMember2024-01-012024-09-300001808220us-gaap:NoncontrollingInterestMember2024-01-012024-09-300001808220us-gaap:CommonClassAMemberus-gaap:CommonStockMember2024-01-012024-09-300001808220us-gaap:AdditionalPaidInCapitalMember2024-01-012024-09-300001808220us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-09-300001808220us-gaap:CommonClassAMemberus-gaap:TreasuryStockCommonMember2024-01-012024-09-300001808220us-gaap:CommonClassBMemberus-gaap:CommonStockMember2024-01-012024-09-300001808220srt:RevisionOfPriorPeriodReclassificationAdjustmentMember2024-01-012024-09-300001808220srt:ScenarioForecastMember2025-10-012025-12-310001808220us-gaap:TradeNamesMember2025-07-012025-09-300001808220us-gaap:TradeNamesMember2025-01-012025-09-300001808220goco:ComputerSoftwareAndPropertyAndEquipmentMember2025-01-012025-09-300001808220goco:ComputerSoftwareAndPropertyAndEquipmentMember2025-07-012025-09-300001808220us-gaap:DevelopedTechnologyRightsMember2025-09-300001808220us-gaap:CustomerRelationshipsMember2025-09-300001808220us-gaap:TradeNamesMember2025-09-300001808220us-gaap:DevelopedTechnologyRightsMember2024-12-310001808220us-gaap:CustomerRelationshipsMember2024-12-310001808220us-gaap:TradeNamesMember2024-12-310001808220us-gaap:SecuredDebtMember2025-09-300001808220us-gaap:SecuredDebtMember2024-12-310001808220us-gaap:RevolvingCreditFacilityMember2025-09-300001808220us-gaap:RevolvingCreditFacilityMember2024-12-310001808220us-gaap:SecuredDebtMembergoco:ExistingTermLoanFacilityMember2024-11-040001808220us-gaap:SecuredDebtMembergoco:ExistingTermLoanFacilityMember2025-03-310001808220us-gaap:SecuredDebtMembergoco:ExistingTermLoanFacilityMember2025-03-012025-03-310001808220us-gaap:SecuredDebtMembergoco:AlternateBaseRateMembergoco:ExistingTermLoanFacilityMember2025-09-302025-09-300001808220us-gaap:SecuredDebtMemberus-gaap:SecuredOvernightFinancingRateSofrMembergoco:ExistingTermLoanFacilityMember2025-09-302025-09-300001808220us-gaap:RevolvingCreditFacilityMembergoco:ClassA1RevolvingCreditFacilityMember2025-09-300001808220us-gaap:RevolvingCreditFacilityMembergoco:ClassARevolvingCreditFacilityMember2024-12-310001808220us-gaap:RevolvingCreditFacilityMembergoco:AlternateBaseRateMembergoco:ClassARevolvingCreditFacilityMember2025-01-012025-09-300001808220us-gaap:RevolvingCreditFacilityMemberus-gaap:SecuredOvernightFinancingRateSofrMembergoco:ClassARevolvingCreditFacilityMember2025-01-012025-09-300001808220us-gaap:RevolvingCreditFacilityMembergoco:ClassARevolvingCreditFacilityMember2025-01-012025-09-300001808220us-gaap:SecuredDebtMembergoco:ExistingTermLoanFacilityMember2025-06-300001808220us-gaap:RevolvingCreditFacilityMembergoco:AdjustedTermSOFRMembergoco:TermLoanFacilitiesAndorClassARevolvingLoansMember2025-08-062025-08-060001808220us-gaap:RevolvingCreditFacilityMembergoco:AdjustedTermSOFRPayableInCashMembergoco:TermLoanFacilitiesAndorClassARevolvingLoansMember2025-08-062025-08-060001808220us-gaap:RevolvingCreditFacilityMembergoco:TermLoanFacilitiesAndorClassARevolvingLoansMember2025-08-062025-08-060001808220us-gaap:SecuredDebtMembergoco:SuperpriorityFacilityMemberus-gaap:LineOfCreditMember2025-08-060001808220us-gaap:SecuredDebtMembergoco:SuperpriorityNewMoneyTermLoansMemberus-gaap:LineOfCreditMember2025-08-060001808220us-gaap:SecuredDebtMembergoco:SuperpriorityNewMoneyTermLoansMemberus-gaap:DebtInstrumentRedemptionPeriodOneMemberus-gaap:LineOfCreditMember2025-08-060001808220us-gaap:SecuredDebtMembergoco:SuperpriorityNewMoneyTermLoansMemberus-gaap:DebtInstrumentRedemptionPeriodTwoMemberus-gaap:LineOfCreditMember2025-08-060001808220us-gaap:SecuredDebtMembergoco:SuperpriorityRollUpTermLoansMemberus-gaap:LineOfCreditMember2025-08-060001808220us-gaap:SecuredDebtMembergoco:SuperpriorityNewMoneyTermLoansMemberus-gaap:SubsequentEventMemberus-gaap:DebtInstrumentRedemptionPeriodTwoMemberus-gaap:LineOfCreditMember2025-10-010001808220us-gaap:SecuredDebtMembergoco:SuperpriorityNewMoneyTermLoansMemberus-gaap:SubsequentEventMemberus-gaap:DebtInstrumentRedemptionPeriodTwoMemberus-gaap:LineOfCreditMember2025-11-020001808220us-gaap:SecuredDebtMembergoco:SuperpriorityNewMoneyTermLoansMemberus-gaap:SubsequentEventMemberus-gaap:DebtInstrumentRedemptionPeriodTwoMemberus-gaap:LineOfCreditMember2025-10-012025-10-310001808220us-gaap:SecuredDebtMembergoco:SuperpriorityNewMoneyTermLoansMemberus-gaap:SubsequentEventMemberus-gaap:DebtInstrumentRedemptionPeriodTwoMemberus-gaap:LineOfCreditMember2025-11-012025-11-140001808220goco:AdjustedTermSOFRMembergoco:SuperpriorityFacilityMemberus-gaap:LineOfCreditMember2025-08-062025-08-060001808220us-gaap:BaseRateMembergoco:SuperpriorityFacilityMemberus-gaap:LineOfCreditMember2025-08-062025-08-060001808220goco:SuperpriorityNewMoneyTermLoansMemberus-gaap:DebtInstrumentRedemptionPeriodOneMemberus-gaap:LineOfCreditMember2025-08-060001808220goco:SuperpriorityNewMoneyTermLoansMemberus-gaap:DebtInstrumentRedemptionPeriodTwoMemberus-gaap:LineOfCreditMember2025-08-060001808220goco:SuperpriorityNewMoneyTermLoansMemberus-gaap:DebtInstrumentRedemptionPeriodThreeMemberus-gaap:LineOfCreditMember2025-08-060001808220goco:SuperpriorityNewMoneyTermLoansMemberus-gaap:LineOfCreditMember2025-09-300001808220us-gaap:SecuredDebtMembergoco:SuperpriorityFacilityMemberus-gaap:LineOfCreditMember2025-08-062025-08-060001808220us-gaap:SecuredDebtMembergoco:ExistingTermLoanFacilityMember2025-09-300001808220us-gaap:SecuredDebtMembergoco:ExistingTermLoanFacilityMember2024-12-310001808220us-gaap:RevolvingCreditFacilityMembergoco:ClassARevolvingCreditFacilityMember2025-09-300001808220us-gaap:RevolvingCreditFacilityMembergoco:ClassA1RevolvingCreditFacilityMember2024-12-310001808220us-gaap:SecuredDebtMembergoco:SuperpriorityNewMoneyTermLoansMemberus-gaap:LineOfCreditMember2025-09-300001808220us-gaap:SecuredDebtMembergoco:SuperpriorityRollUpTermLoansMemberus-gaap:LineOfCreditMember2025-09-300001808220goco:SuperpriorityFacilityMemberus-gaap:DebtInstrumentRedemptionPeriodOneMemberus-gaap:LineOfCreditMember2025-08-060001808220goco:SuperpriorityFacilityMemberus-gaap:DebtInstrumentRedemptionPeriodTwoMemberus-gaap:LineOfCreditMember2025-08-060001808220goco:SuperpriorityFacilityMemberus-gaap:DebtInstrumentRedemptionPeriodThreeMemberus-gaap:LineOfCreditMember2025-08-060001808220goco:SuperpriorityFacilityMemberus-gaap:DebtInstrumentRedemptionPeriodFourMemberus-gaap:LineOfCreditMember2025-08-060001808220goco:SuperpriorityFacilityMemberus-gaap:DebtInstrumentRedemptionPeriodFiveMemberus-gaap:LineOfCreditMember2025-08-060001808220us-gaap:CommonClassAMember2020-07-310001808220us-gaap:CommonClassBMember2020-07-3100018082202020-07-3100018082202020-07-012020-07-310001808220goco:ContinuingEquityOwnersAndPermittedTransfereesMember2020-07-012020-07-310001808220us-gaap:CommonClassAMember2020-07-012020-07-310001808220us-gaap:CommonClassBMember2020-07-012020-07-310001808220goco:GoHealthHoldingsLLCMember2020-07-012020-07-310001808220goco:GoHealthHoldingsLLCMember2025-07-012025-09-300001808220goco:GoHealthHoldingsLLCMember2025-01-012025-09-300001808220goco:GoHealthHoldingsLLCMember2024-07-012024-09-300001808220goco:GoHealthHoldingsLLCMember2024-01-012024-09-300001808220us-gaap:SeriesAPreferredStockMember2022-09-230001808220us-gaap:SeriesAPreferredStockMember2022-09-232022-09-230001808220us-gaap:RedeemableConvertiblePreferredStockMember2022-09-230001808220us-gaap:ConvertiblePreferredStockMember2022-09-230001808220us-gaap:RedeemableConvertiblePreferredStockMember2025-07-012025-09-300001808220us-gaap:RedeemableConvertiblePreferredStockMember2025-01-012025-09-300001808220us-gaap:RedeemableConvertiblePreferredStockMember2024-07-012024-09-300001808220us-gaap:RedeemableConvertiblePreferredStockMember2024-01-012024-09-300001808220us-gaap:SeriesAPreferredStockMember2025-09-300001808220us-gaap:CommonClassAMember2022-09-230001808220srt:MinimumMemberus-gaap:SeriesAPreferredStockMember2022-09-232022-09-2300018082202022-09-232022-09-230001808220srt:MaximumMember2022-09-2300018082202022-09-230001808220us-gaap:RevolvingCreditFacilityMembergoco:TermLoanFacilitiesAndorClassARevolvingLoansMemberus-gaap:DebtInstrumentRedemptionPeriodOneMember2025-08-060001808220us-gaap:RevolvingCreditFacilityMembergoco:TermLoanFacilitiesAndorClassARevolvingLoansMemberus-gaap:DebtInstrumentRedemptionPeriodTwoMember2025-08-060001808220us-gaap:SellingAndMarketingExpenseMember2025-07-012025-09-300001808220us-gaap:SellingAndMarketingExpenseMember2024-07-012024-09-300001808220us-gaap:SellingAndMarketingExpenseMember2025-01-012025-09-300001808220us-gaap:SellingAndMarketingExpenseMember2024-01-012024-09-300001808220goco:ConsumerCareAndEnrollmentMember2025-07-012025-09-300001808220goco:ConsumerCareAndEnrollmentMember2024-07-012024-09-300001808220goco:ConsumerCareAndEnrollmentMember2025-01-012025-09-300001808220goco:ConsumerCareAndEnrollmentMember2024-01-012024-09-300001808220us-gaap:TechnologyServiceMember2025-07-012025-09-300001808220us-gaap:TechnologyServiceMember2024-07-012024-09-300001808220us-gaap:TechnologyServiceMember2025-01-012025-09-300001808220us-gaap:TechnologyServiceMember2024-01-012024-09-300001808220us-gaap:GeneralAndAdministrativeExpenseMember2025-07-012025-09-300001808220us-gaap:GeneralAndAdministrativeExpenseMember2024-07-012024-09-300001808220us-gaap:GeneralAndAdministrativeExpenseMember2025-01-012025-09-300001808220us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-09-300001808220us-gaap:StockCompensationPlanMember2025-01-012025-09-300001808220us-gaap:StockCompensationPlanMember2024-01-012024-09-300001808220us-gaap:RedeemableConvertiblePreferredStockMember2025-01-012025-09-300001808220us-gaap:RedeemableConvertiblePreferredStockMember2024-01-012024-09-300001808220us-gaap:CommonClassBMember2025-01-012025-09-300001808220us-gaap:CommonClassBMember2024-01-012024-09-300001808220goco:ETeleQuoteInsuranceIncMember2024-12-3100018082202020-07-170001808220goco:CommissionRevenueExcludingIndividualAndFamilyPlansMember2025-07-012025-09-300001808220goco:CommissionRevenueExcludingIndividualAndFamilyPlansMember2024-07-012024-09-300001808220goco:CommissionRevenueExcludingIndividualAndFamilyPlansMember2025-01-012025-09-300001808220goco:CommissionRevenueExcludingIndividualAndFamilyPlansMember2024-01-012024-09-300001808220goco:PartnerMarketingAndOtherRevenueMember2025-07-012025-09-300001808220goco:PartnerMarketingAndOtherRevenueMember2024-07-012024-09-300001808220goco:PartnerMarketingAndOtherRevenueMember2025-01-012025-09-300001808220goco:PartnerMarketingAndOtherRevenueMember2024-01-012024-09-300001808220goco:AgencyRevenueMember2025-07-012025-09-300001808220goco:AgencyRevenueMember2024-07-012024-09-300001808220goco:AgencyRevenueMember2025-01-012025-09-300001808220goco:AgencyRevenueMember2024-01-012024-09-300001808220goco:NonAgencyRevenueMember2025-07-012025-09-300001808220goco:NonAgencyRevenueMember2024-07-012024-09-300001808220goco:NonAgencyRevenueMember2025-01-012025-09-300001808220goco:NonAgencyRevenueMember2024-01-012024-09-300001808220goco:MedicareRevenueMember2025-07-012025-09-300001808220goco:MedicareRevenueMember2024-07-012024-09-300001808220goco:MedicareRevenueMember2025-01-012025-09-300001808220goco:MedicareRevenueMember2024-01-012024-09-300001808220goco:OtherNonAgencyRevenueMember2025-07-012025-09-300001808220goco:OtherNonAgencyRevenueMember2024-07-012024-09-300001808220goco:OtherNonAgencyRevenueMember2025-01-012025-09-300001808220goco:OtherNonAgencyRevenueMember2024-01-012024-09-300001808220goco:OtherAgencyRevenueMember2025-07-012025-09-300001808220goco:OtherAgencyRevenueMember2024-07-012024-09-300001808220goco:OtherAgencyRevenueMember2025-01-012025-09-300001808220goco:OtherAgencyRevenueMember2024-01-012024-09-300001808220us-gaap:ProductAndServiceOtherMember2025-07-012025-09-300001808220us-gaap:ProductAndServiceOtherMember2024-07-012024-09-300001808220us-gaap:ProductAndServiceOtherMember2025-01-012025-09-300001808220us-gaap:ProductAndServiceOtherMember2024-01-012024-09-300001808220goco:CommissionMember2024-12-310001808220goco:CommissionMember2023-12-310001808220goco:CommissionMember2025-01-012025-09-300001808220goco:CommissionMember2024-01-012024-09-300001808220goco:CommissionMember2025-09-300001808220goco:CommissionMember2024-09-300001808220goco:UnitedMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2025-07-012025-09-300001808220goco:UnitedMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-07-012024-09-300001808220goco:UnitedMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2025-01-012025-09-300001808220goco:UnitedMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-01-012024-09-300001808220goco:HumanaMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2025-07-012025-09-300001808220goco:HumanaMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-07-012024-09-300001808220goco:HumanaMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2025-01-012025-09-300001808220goco:HumanaMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-01-012024-09-300001808220goco:ElevanceHealthMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2025-07-012025-09-300001808220goco:ElevanceHealthMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-07-012024-09-300001808220goco:ElevanceHealthMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2025-01-012025-09-300001808220goco:ElevanceHealthMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-01-012024-09-300001808220goco:ColonialPennMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2025-07-012025-09-300001808220goco:ColonialPennMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-07-012024-09-300001808220goco:ColonialPennMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2025-01-012025-09-300001808220goco:ColonialPennMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-01-012024-09-300001808220goco:OneCustomerMemberus-gaap:CustomerConcentrationRiskMembergoco:AccountsReceivableAndUnbilledReceivablesMember2025-01-012025-09-300001808220goco:OneCustomerMemberus-gaap:CustomerConcentrationRiskMembergoco:AccountsReceivableAndUnbilledReceivablesMember2025-09-300001808220goco:TwoCustomersMemberus-gaap:CustomerConcentrationRiskMembergoco:AccountsReceivableAndUnbilledReceivablesMember2024-01-012024-12-310001808220goco:TwoCustomersMemberus-gaap:CustomerConcentrationRiskMembergoco:AccountsReceivableAndUnbilledReceivablesMember2024-12-310001808220us-gaap:SubsequentEventMember2025-11-032025-11-030001808220us-gaap:SubsequentEventMember2025-11-03

WASHINGTON, DC 20549

(Mark One)

For the quarterly period ended September 30, 2025

For the transition period from                      to                     

Commission File Number: 001-39390

(Exact name of registrant as specified in its charter)

_________________________

(Registrant’s telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

_________________________

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒    No  ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ☐    No  ☒

As of November 6, 2025, the registrant had 16,093,116 shares of Class A common stock, $0.0001 par value per share, outstanding and 12,620,884 shares of Class B common stock, $0.0001 par value per share, outstanding.

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These forward-looking statements are made in reliance upon the safe harbor provision of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q may be forward-looking statements. Statements regarding our liquidity, future results of operations and financial position, business strategy and plans and objectives of management for future operations, including, among others, statements regarding the expected results of the strategic capital and governance actions entered into on August 6, 2025, our pursuit of strategic alternatives and other shifts in our strategy, health plans’ respective decisions related to plan offerings and associated compensation for broker services, our expected growth, future capital expenditures, debt service obligations, future ability to continue as a going concern, adoption and use of artificial intelligence technologies, the impact on our business from regulatory changes, the impact on our business from the acquisition of e-TeleQuote Insurance, Inc. (“e-TeleQuote”) and our ability to successfully integrate e-TeleQuote’s operations, technologies and employees into our business, are forward-looking statements.

In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “aims,” “expects,” “plans,” “anticipates,” “could,” “intends,” “targets,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” “likely,” “future” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this Quarterly Report on Form 10-Q are only predictions, projections and other statements about future events that are based on current expectations and assumptions. Accordingly, we caution you that any such forward-looking statements are not guarantees of future performance and are subject to risks, assumptions and uncertainties that are difficult to predict. Although we believe that the expectations reflected in these forward-looking statements are reasonable as of the date made, actual results may prove to be materially different from the results expressed or implied by the forward-looking statements.

These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and are subject to a number of important factors that could cause actual results to differ materially from those in the forward-looking statements, including the factors described in the sections titled “Summary Risk Factors,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (“2024 Annual Report on Form 10-K”), our Quarterly Report on Form 10-Q for the first quarter ended March 31, 2025, our Quarterly Report on Form 10-Q for the second quarter ended June 30, 2025, this Quarterly Report on Form 10-Q for the third quarter ended September 30, 2025 and in our other filings with the Securities and Exchange Commission.

You should read this Quarterly Report on Form 10-Q and the documents that we reference in this Quarterly Report on Form 10-Q completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

As used in this Quarterly Report on Form 10-Q, unless the context otherwise requires:

•“We,” “us,” “our,” the “Company,” “GoHealth” and similar references refer to GoHealth, Inc., and unless otherwise stated, all of its direct and indirect subsidiaries, including GoHealth Holdings, LLC (“GHH, LLC”).

•“Blocker Company” refers to an entity affiliated with Centerbridge that was an indirect owner of LLC Interests in GHH, LLC prior to the Transactions and is taxable as a corporation for U.S. federal income tax purposes.

•“Blocker Shareholders” refer to entities affiliated with Centerbridge, the owners of the Blocker Company prior to the Transactions, who exchanged their interests in the Blocker Company for shares of our Class A common stock and cash in connection with the consummation of the Transactions.

•“Centerbridge” refers to certain investment funds and other entities affiliated with CCP III Cayman GP Ltd., a Cayman Islands exempted company over which CCP III Cayman GP Ltd. has voting control (including any such fund or entity formed to hold shares of Class A common stock for the Blocker Shareholders).

•“Continuing Equity Owners” refer collectively to direct or indirect holders of LLC Interests and our Class B common stock immediately following consummation of the Transactions, including Centerbridge, NVX Holdings, our Founders, the Former Profits Unit Holders and certain executive officers, employees and other minority investors and their respective permitted transferees who may, following the consummation of our IPO, exchange at each of their respective options (subject in certain circumstances to time-based vesting requirements and certain other restrictions), in whole or in part from time to time, their LLC Interests (along with an equal number of shares of Class B common stock (and such shares shall be immediately cancelled)) for, at our election (determined solely by our independent directors (within the meaning of the listing rules of The Nasdaq Global Market (the “Nasdaq Rules”) who are disinterested)), cash or newly-issued shares of our Class A common stock.

•“Founders” refer to Brandon Cruz, our Co-Founder and Co-Chairman of the Board of Directors and Clinton Jones, our Co-Founder and Co-Chairman of the Board of Directors.

•“Former Profits Unit Holders” refer collectively to certain of our directors and certain current and former officers and employees, in each case, who directly or indirectly held existing vested and unvested profits units, which were comprised of profits units that have time-based vesting conditions and profits units that have performance-based vesting conditions, of GHH, LLC pursuant to GHH, LLC’s existing profits unit plan and who received LLC Interests in exchange for their profits units in connection with the Transactions. LLC Interests received in exchange for unvested profits units remain subject to their existing time-based vesting requirements. Profits units with performance-based vesting conditions fully vested as such conditions were met in connection with our IPO.

•“GHH, LLC Agreement” refers to GHH, LLC’s amended and restated limited liability company agreement, as further amended, which became effective substantially concurrently with or prior to the consummation of our IPO.

•“LLC Interests” refer to the common units of GHH, LLC, including those that we purchased with a portion of the net proceeds from our IPO.

•“LTV” refers to the Lifetime Value of Commissions, which we define as aggregate commissions estimated to be collected over the estimated life of all commissionable Submissions for the relevant period based on multiple factors, including but not limited to, contracted commission rates, health plan partner mix and expected policy persistency with applied constraints.

•“Norvax” refers to Norvax, LLC, a Delaware limited liability company and a subsidiary of GHH, LLC.

•“NVX Holdings” refers to NVX Holdings, Inc., a Delaware corporation that is controlled by the Founders.

•“Subscribers” refers to the lenders (or their affiliates) holding Class A Revolving Loans and Existing Term Loans that received an aggregate of 4,766,219 shares of Class A common stock, allocated pro rata, in connection with Amendment No. 14 to the Company’s Existing Credit Agreement.

•“Transactions” refer to our IPO and certain organizational transactions that were effected in connection with our IPO, and the application of the net proceeds therefrom.

GoHealth, Inc. is a holding company and the sole managing member of GHH, LLC, and its principal asset consists of LLC Interests.

Throughout this Quarterly Report on Form 10-Q, we use a number of non-GAAP financial measures. Non-GAAP financial measures are supplemental measures of our performance that are derived from our consolidated financial information, but which are not presented in our Condensed Consolidated Financial Statements prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). We define these non-GAAP financial measures as follows:

•“Adjusted EBITDA” represents, as applicable for the period, EBITDA as further adjusted for certain items discussed in Item 2. “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”

•“Adjusted EBITDA Margin” refers to Adjusted EBITDA divided by net revenues.

•“EBITDA” represents net income (loss) before interest expense, income tax expense (benefit) and depreciation and amortization expense.

We believe that excluding certain items from our GAAP results allows management to better understand our consolidated financial performance from period to period and better project our future consolidated financial performance as forecasts are developed at a level of detail different from that used to prepare GAAP-based financial measures. Moreover, we believe these non-GAAP financial measures provide our stakeholders with useful information to help them evaluate our operating results by facilitating an enhanced understanding of our operating performance and enabling them to make more meaningful period to period comparisons. Adjusted EBITDA is the primary non-GAAP financial performance measure used by management to evaluate the business and monitor the results of operations, as well as a basis for certain compensation programs sponsored by the Company. There are limitations to the use of the non-GAAP financial measures presented in this Quarterly Report on Form 10-Q. For example, our non-GAAP financial measures may not be comparable to similarly titled measures of other companies. Other companies, including companies in our industry, may calculate non-GAAP financial measures differently than we do, limiting the usefulness of those measures for comparative purposes.

The non-GAAP financial measures are not meant to be considered as indicators of performance in isolation from or as a substitute for the most directly comparable financial measures prepared in accordance with GAAP and should be read only in conjunction with financial information presented on a GAAP basis. Reconciliations of each of EBITDA, Adjusted EBITDA and Adjusted EBITDA Margin to its most directly comparable GAAP financial measure are presented in the tables within Item 2. “Management’s Discussion and Analysis of Financial Condition and Results of Operations” of this Quarterly Report on Form 10-Q. We encourage you to review the reconciliations in conjunction with the presentation of the non-GAAP financial measures for each of the periods presented. In future periods, we may exclude similar items, may incur income and expenses similar to these excluded items and may include other expenses, costs and non-routine items.

Throughout this Quarterly Report on Form 10-Q, we use a number of business and operating metrics to evaluate our business performance and facilitate our operations. The most relevant business and operating metrics are as follows:

•“Direct Operating Cost of Submission” is an operating metric that represents costs directly attributable to Submissions generated during a reporting period and excludes costs that are indirect or fixed. Direct Operating Cost of Submission is comprised of the portion of the respective operating expenses for revenue share, marketing and advertising and consumer care and enrollment that are directly related to the Submissions generated in the reporting period.

•“Direct Operating Cost per Submission” is an operating metric that represents the average performance of Submissions generated during a reporting period. Direct Operating Cost per Submission refers to (x) Direct Operating Cost of Submission for a reporting period divided by (y) the number of Submissions generated for such period.

•“Sales/Direct Operating Cost of Submission” represents (x) the numerator of Sales per Submission, as defined below, divided by (y) Direct Operating Cost of Submission.

•“Sales per Submission” is an operating metric that represents the average performance of Submissions generated during a reporting period. Sales per Submission measures revenues only from the Submissions generated in the period and excludes items that are unrelated to such Submissions, including any impact of revenue adjustments recorded in the period, but relating to performance obligations satisfied in prior periods. Sales per Submission equals (x) the sum of (i) Medicare agency revenues, comprised of the expected amount of initial commission revenue and any renewal commissions to be paid from the health plan partners on such placement as long as the policyholder remains with the same insurance product, as well as partner marketing and other revenue, (ii) Medicare non-agency revenues, comprised of the enrollment and engagement services for which cash is collected in advance or in close proximity to the point in time revenue is recognized, and (iii) revenues from GoHealth Protect, divided by (y) the number of Submissions generated for such period.

•“Submission” refers to either (i) a completed Medicare application with our licensed agent that is submitted to the health plan partner and subsequently approved by the health plan partner during the indicated period, (ii) a transfer by our agent to the health plan partner through the Encompass operating model during the indicated period or (iii) a completed GoHealth Protect application with our licensed agent that is submitted, approved by the health plan partner, and for which the payment information was received by the health plan partner during the indicated period.

Sales per Submission and Direct Operating Cost per Submission are key operating metrics used by management to understand the Company’s underlying financial performance and trends. For further discussion, see Item 2. “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”

						Sep. 30, 2025						Dec. 31, 2024
Assets
Current assets:
Cash and cash equivalents						$	32,076					$	40,921
Accounts receivable, net						2						4,452
Commissions receivable - current						238,947						320,399
Prepaid expense and other current assets						16,437						34,639
Total current assets						287,462						400,411
Commissions receivable - non-current						725,074						733,161
Operating lease ROU asset						10,138						19,317
Property, equipment, and capitalized software, net						5,558						29,320
Intangible assets, net						—						302,497
Other long-term assets						2,254						3,717
Total assets						$	1,030,486					$	1,488,423
Liabilities, Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit)
Current liabilities:
Accounts payable						11,853						14,591
Accrued liabilities						60,913						121,346
Commissions payable - current						65,088						98,771
Short-term operating lease liability						4,916						5,705
Deferred revenue						29,195						53,720
Current portion of long-term debt						—						39,500
Other current liabilities						3,717						4,419
Total current liabilities						175,682						338,052
Non-current liabilities:
Commissions payable - non-current						169,049						177,656
Long-term operating lease liability						29,958						34,900
Deferred tax liability						22,754						22,350
Long-term debt, net of current portion						581,844						447,865
Other non-current liabilities						2,227						9,200
Total non-current liabilities						805,832						691,971
Commitments and Contingencies (Note 11)
Series A redeemable convertible preferred stock — $0.0001 par value; 50 shares authorized; 50 shares issued and outstanding as of both September 30, 2025 and December 31, 2024. Liquidation preference of $57.5 million and $54.6 million as of September 30, 2025 and December 31, 2024, respectively.						55,880						52,962
Stockholders’ equity (deficit):
Class A common stock – $0.0001 par value; 1,100,000 shares authorized as of both September 30, 2025 and December 31, 2024; 16,803 and 10,614 shares issued as of September 30, 2025 and December 31, 2024, respectively; 16,032 and 10,292 shares outstanding as of September 30, 2025 and December 31, 2024, respectively.						1						1
Class B common stock – $0.0001 par value; 615,825 and 615,917 shares authorized as of September 30, 2025 and December 31, 2024, respectively; 12,621 and 12,711 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively.						1						1
Preferred stock – $0.0001 par value; 20,000 shares authorized (including 50 shares of Series A redeemable convertible preferred stock authorized and 200 shares of Series A-1 convertible preferred stock authorized); 50 shares issued and outstanding as of both September 30, 2025 and December 31, 2024.						—						—
Series A-1 convertible preferred stock— $0.0001 par value; 200 shares authorized; no shares issued and outstanding as of both September 30, 2025 and December 31, 2024.						—						—
Treasury stock – at cost; 771 and 322 shares of Class A common stock as of September 30, 2025 and December 31, 2024, respectively.						(9,280)						(4,150)
Additional paid-in capital						725,242						669,346
Accumulated other comprehensive income (loss)						(55)						(151)
Accumulated deficit						(647,739)						(423,208)
Total stockholders’ equity (deficit) attributable to GoHealth, Inc.						68,170						241,839
Non-controlling interests						(75,078)						163,599
Total stockholders’ equity (deficit)						(6,908)						405,438
Total liabilities, redeemable convertible preferred stock and stockholders’ equity (deficit)						$	1,030,486					$	1,488,423

GoHealth (the “Company”) is a leading health insurance marketplace and Medicare-focused digital health company whose purpose is to compassionately ensure consumers’ peace of mind when making healthcare decisions so they can focus on living life. With a widely scalable end-to-end platform and substantial presence in the Medicare landscape, GoHealth believes it is uniquely positioned as a trusted partner to the 67 million Medicare-eligible Americans, as well as the 11,000 Americans becoming eligible each day, as they navigate one of life's most important purchasing decisions. For many of these consumers, enrolling in a health insurance plan is confusing and difficult, and seemingly small differences between health plans may lead to significant out-of-pocket costs or lack of access to critical providers and medicines. GoHealth aims to simplify the process by offering education, comparison guidance, transparency and choice. This includes providing a large selection of leading health plan choices, advice informed by consumers’ specific needs, transparency of health plan benefits and fit, assistance accessing available government subsidies and a high-touch consumer care team. GoHealth partners with health plans that provide access to high-quality health plans across all 50 states and the District of Columbia.

GoHealth primarily offers Medicare plans, including, but not limited to, Medicare Advantage, Medicare Supplement and prescription drug plans. Its proprietary technology platform leverages modern machine-learning algorithms, powered by over two decades of insurance purchasing behavior, to reimagine the process of matching a health plan to a consumer’s specific needs. GoHealth’s unbiased, technology-driven marketplace coupled with highly-skilled licensed agents has facilitated the enrollment of millions of consumers in Medicare plans since its inception. Health plan partners benefit from the GoHealth platform by gaining access to the large and rapidly growing Medicare-eligible population. GoHealth believes health plan partners utilize its large-scale data, technology and efficient marketing processes to maximize scale and reduce their cost of submission, compared to health plan partner-employed agent workforces.

GoHealth believes its streamlined, consumer-centric Encompass operating model drives both high-quality enrollments and a strong consumer experience. The Company strives to be a trusted, high-quality enrollment partner for both consumers and health plan partners.

Refer to the Liquidity and Going Concern section in this Note 1 for an update about our business.

The Company was incorporated in Delaware on March 27, 2020 for the purpose of facilitating an initial public offering (the “IPO”) and other related transactions in order to carry on the business of GHH, LLC, a Delaware limited liability company, and its controlled subsidiaries (collectively, “GHH, LLC”). Following the IPO and pursuant to a reorganization into a holding company structure, the Company is a holding company and its principal asset is a controlling equity interest in GHH, LLC. As the sole managing member of GHH, LLC, the Company operates and controls all of the business and affairs of GHH, LLC, and through GHH, LLC and its subsidiaries, conducts its business. As a result, the Company consolidates GHH, LLC’s financial results in its Condensed Consolidated Financial Statements and reports non-controlling interests for the economic interest in GHH, LLC held by the Continuing Equity Owners.

The accompanying Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information, but do not include all information and footnote disclosures required under GAAP for annual financial statements. The accompanying Condensed Consolidated Financial Statements and related notes should be read in conjunction with the audited Consolidated Financial Statements and related notes included in the Company’s 2024 Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission on February 27, 2025. In the opinion of management, the interim Condensed Consolidated Financial Statements include all adjustments, consisting only of normal recurring adjustments, necessary for the fair presentation of the Company’s financial position, results of operations and cash flows as of the dates and for the periods presented. All intercompany transactions and balances are eliminated in consolidation.

Certain prior period amounts have been reclassified to conform with the current period presentation. The Company reclassified $19.3 million related to certain commissions payable to external agents from other current liabilities to commissions payable - current on the Condensed Consolidated Statements of Cash Flows for the period ended September 30, 2024 to conform to current period presentation.

There have been no material changes to the Company’s significant accounting policies from those disclosed in the notes to the Company’s audited Consolidated Financial Statements as of and for the year ended December 31, 2024, which were included in the Company’s 2024 Annual Report on Form 10-K.

These Condensed Consolidated Financial Statements have been prepared in accordance with GAAP applicable to a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business within twelve months after the date that these Condensed Consolidated Financial Statements are issued.

Under the Company’s Superpriority Credit Agreement and Amendment No. 14 to its existing term loan (as defined and described further in Note 4, “Long-Term Debt”), the Company is required to meet minimum liquidity covenants and make scheduled principal and interest payments. As of September 30, 2025, the Company was in compliance with all of its financial covenants; however, management’s current financial projections indicate that, based on the Company’s current business plan, there is a significant likelihood that the Company will be unable to maintain compliance with its covenants within the twelve months after these Condensed Consolidated Financial Statements are issued, unless the mitigating plans described below are implemented successfully.

To mitigate these uncertainties, management has implemented and is actively pursuing various strategic alternatives, including, among others, refinancings, securitizations, mergers, acquisitions or restructurings. Starting in the third quarter of 2025, management implemented cash management initiatives to further reduce operating expenses and improve cash flows including a reduction in force during the fourth quarter of 2025, impacting approximately 487 employees. In addition, management has plans to implement further cost savings to maintain compliance with its debt covenants. While management believes it is probable these plans will be executed successfully, they cannot guarantee such plans will be implemented successfully.

The preparation of the Condensed Consolidated Financial Statements in conformity with GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities at the date of the Condensed Consolidated Financial Statements and the reported amounts of revenues and expenses during the reporting periods. The Company bases its estimates on historical experience and various other assumptions that management believes are reasonable under the circumstances, the results of which form the basis for making judgments about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.

The Medicare annual enrollment period (“AEP”) occurs from October 15th to December 7th. As a result, and in general, the Company experiences an increase in the number of Submissions during the fourth quarter and an increase in expense related to the Submissions during the third and fourth quarters. Additionally, as a result of the annual Medicare Advantage open enrollment period that occurs from January 1st to March 31st, Submissions are typically second-highest in the first quarter. The second and third quarters are known as special election periods, during which Submissions are typically lowest. A significant portion of the Company’s marketing and advertising expenses is driven by the number of health insurance applications submitted through the Company. Marketing and advertising expenses are generally higher in the fourth quarter during AEP, but because commissions from approved consumers are paid to the Company over time, the Company’s operating cash flows could be adversely impacted by a substantial increase in marketing and advertising expenses as a result of a higher volume of Submissions during the fourth quarter or positively impacted by a substantial decline in marketing and advertising expenses as a result of lower volume of Submissions during the fourth quarter.

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures ("ASU 2023-09"). ASU 2023-09 enhanced annual disclosures regarding the income tax rate reconciliation and income taxes paid information. ASU 2023-09 is effective for annual periods beginning after December 15, 2024 for public business entities and annual periods beginning after December 15, 2025 for all other entities. The Company is currently assessing the impact on its related disclosures.

In November 2024, the FASB issued ASU 2024-03, Income Statement: Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (“ASU 2024-03”), which requires disclosure about the types of costs and expenses included in certain expense captions presented on the income statement. The new disclosure requirements are effective for the Company’s annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027, with early adoption permitted. The Company is currently in the process of evaluating the impact of this pronouncement on our related disclosures.

The Company defines fair value as the price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques the Company uses to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The Company has applied the provisions of fair value accounting for purposes of computing the fair value of financial instruments for disclosure purposes as presented below.

The carrying amount of certain financial instruments, including cash and cash equivalents, accounts receivable, unbilled receivables, accounts payable and accrued expenses approximate fair value due to the short maturity of these instruments. The carrying value of debt approximates fair value due to the variable nature of interest rates.

During the three months ended September 30, 2025, the Company identified indicators of impairment related to its indefinite-lived intangible assets and long-lived assets, primarily related to revised long-term forecasts, reflecting the Company’s intentional pullback on Medicare Advantage activity in response to tightening health plan economics such as a reduction in the number of marketable and/or commissionable plans offered by health plan partners. The revised forecasts led to a reduction in the projected future cash flows associated with the Company’s trade name, developed technology and customer relationships and other long-lived assets, triggering an interim impairment assessment. The Company first tested its indefinite-lived trade name intangible asset. The revised forecast led to a reduction in the projected future cash flows associated with the trade name resulting in a $20.0 million and $73.0 million impairment charge for the three and nine months ended September 30, 2025, respectively, which are included in “Indefinite and long-lived asset impairment charges” on the Condensed Consolidated Statements of Operations. The Company also tested its long-lived assets for impairment by first performing a recoverability test, comparing projected undiscounted cash from the use and eventual disposition of the asset group to its carrying value. The recoverability test indicated that the undiscounted cash flows were not sufficient to recover the carrying value of the Company’s asset group. The Company then compared the fair value of the asset group to its carrying value to measure the amount of impairment to record. The impairment charge was then allocated to individual long-lived assets in accordance with ASC 360. As a result, the Company recorded intangible asset impairment charges of $159.0 million for the three and nine months ended September 30, 2025 to write down the carrying value of its definite-lived amortizable intangible assets to zero. The Company also recorded impairment charges related to capitalized software, and property and equipment of $22.7 million for each of the three and nine months ended September 30, 2025.

There was no impairment of indefinite and long-lived assets for the three and nine months ended September 30, 2024. For more information, refer to Note 3, “Intangible Assets, Net.”

During the three months ended September 30, 2025, the Company determined that the fair value of its indefinite-lived trade names and definite-lived amortizable intangible assets no longer exceeded their carrying values. As a result, the Company recorded intangible asset impairment charges of $179.0 million and $232.0 million for the three and nine months ended September 30, 2025, respectively, to write down the carrying values of the indefinite-lived trade names and definite-lived amortizable intangible assets to zero. The intangible asset impairment charges are included in “Indefinite and long-lived asset impairment charges” on the Condensed Consolidated Statements of Operations. There was no impairment of intangible assets for the three and nine months ended September 30, 2024. For more information, refer to Note 2, “Fair Value Measurements.”

The gross carrying amounts, accumulated amortization and net carrying amounts of the Company’s definite-lived amortizable intangible assets, as well as its indefinite-lived intangible trade names, are as follows:

The Company’s long-term debt consisted of the following:

Maturities of long-term debt for each of the next five years is as follows:

On November 4, 2024 (the “Effective Date”), Norvax (the “Borrower”) entered into the Amendment and Restatement Agreement (the “Existing Credit Agreement”) to provide for, among other provisions as further described below, a class of term loan facilities (the “Existing Term Loan Facility” or “Existing Term Loans”) in an aggregate principal amount equal to $475.0 million. Starting March 31, 2025, principal repayments of 2.00% per annum of the initial principal amount were made in equal quarterly installments. In March 2025, the Borrower repaid $2.4 million under this facility. Prior to Amendment No. 14 (as defined and

further described below), at the option of the Borrower, the Existing Term Loan Facility bore interest at either (i) ABR plus 6.50% per annum or (ii) Adjusted Term SOFR plus 7.50% per annum. To the extent not previously paid, the Existing Term Loan Facility, together with all accrued and unpaid interest thereon, is due and payable on November 4, 2029.

In addition to the Existing Term Loan Facility, the Existing Credit Agreement provided for a revolving credit facility with a commitment amount of $88.5 million (the “Class A Revolving Credit Facility”) and a revolving credit facility with a commitment amount of $35.0 million (the “Class A-1 Revolving Credit Facility"). The Class A Revolving Credit Facility bore interest at either (i) ABR plus 5.50% per annum or (ii) SOFR plus 6.50% per annum. The Borrower was required to pay a commitment fee of 0.50% per annum on undrawn amounts under the Class A Revolving Credit Facility. The Class A-1 Revolving Credit Facility was to be made available to the Borrower upon the termination of the Class A Revolving Credit Facility on or prior to June 30, 2025 (which was then further extended pursuant to Amendment No. 13 and Amendment No. 14). Following the entry into Amendment No. 14, the Class A-1 Revolving Credit Facility has been terminated.

On June 30, 2025, the Borrower entered into Amendment No. 13 to the Existing Credit Agreement (“Amendment No. 13”), which modified the Existing Credit Agreement to, among other things, (i) provide that all interest payable for the Existing Term Loan Facility and Class A Revolving Credit Facility occurring on or prior to September 30, 2025 would be payable in-kind, and thus capitalized and added to the respective principal balances, (ii) waive the principal payments of the Existing Term Loan Facility on June 30, 2025 and September 30, 2025, (iii) extend the maturity date of borrowings outstanding under the Class A Revolving Credit Facility from June 30, 2025 to September 30, 2025 (which was then further extended pursuant to Amendment No. 14) and (iv) permit the Borrower to negotiate and consummate a receivables financing, securitization, receivables facility or other similar financing.

Pursuant to Amendment No. 13, the Company incurred $5.6 million in debt issuance costs which are payable in-kind, and thus capitalized and added to the outstanding principal balance. The Company paid an additional $0.4 million in debt issuance costs in cash related to Amendment No. 13. The total debt issuance costs are amortized over the life of the debt to interest expense using the effective interest method.

On August 6, 2025, the Borrower entered into Amendment No. 14 to the Existing Credit Agreement (“Amendment No. 14”), which further amends the Existing Credit Agreement to, among other things, (i) terminate all revolving commitments under the Class A-1 Revolving Credit Facility (with no revolving loans under the Class A-1 Revolving Credit Facility being outstanding on August 6, 2025), (ii) terminate all Class A revolving commitments and extend the maturity date of the remaining Class A revolving loans outstanding to August 5, 2029 (the “Class A Loans”), (iii) permit the Borrower to pay in-kind a portion of the interest on the outstanding Existing Term Loans and Class A Loans with such loan accruing interest at a rate equal to Adjusted Term SOFR plus 8.00% per annum, of which an amount of interest equal to at least Adjusted Term SOFR plus 4.50% is payable in cash with the remainder of such interest paid in-kind and (iv) waive the principal payments of the Existing Term Loans until December 31, 2026. Following Amendment No. 14, amounts repaid or prepaid in respect of the Class A Loans may not be reborrowed. As consideration for, and as a condition to, the lenders’ entry into Amendment No. 14, on August 6, 2025, the Company issued to lenders (or their affiliates) holding Class A Loans and Existing Term Loans (for these purposes, the “Subscribers”), pro rata based on their respective holdings thereof, an aggregate of 4,766,219 shares of Class A common stock.

On August 6, 2025 (the “Closing Date”), the Borrower entered into the Superpriority Senior Secured Credit Agreement (the “Superpriority Credit Agreement”). The Superpriority Credit Agreement governs a senior secured superpriority term loan facility in an aggregate principal amount of $115.0 million (the “Superpriority Facility”) consisting of (a) $80.0 million in new-money term loans (together, the “New Money Term Loans”), of which (i) $40.0 million was funded on the closing date (the “Initial New Money Term Loans”) and (ii) $40.0 million is available as delayed-draw term loans (the “Delayed Draw Term Loans”), and (b) $35.0 million of roll-up term loans funded on the closing date (the “Roll-Up Term Loans” and together with the New Money Term Loans, the “Superpriority Term Loans”) resulting from the cashless conversion of a corresponding amount of Class A Loans at par that were outstanding under the Existing Credit Agreement into term loans on a dollar-for-dollar basis. Provided that no default or event of default has occurred and is continuing, the Delayed Draw Term Loans will be available to the Borrower on or after October 1, 2025, with the aggregate principal amount of such loans funded prior to November 1, 2025 not to exceed $15.0 million and prior to December 1, 2025, not to exceed $30.0 million, with the full amount available thereafter. Pursuant to this agreement, the Company borrowed $15.0 million of the Delayed Draw Term Loans in October 2025 and another $15.0 million in November 2025.

The Superpriority Facility matures on August 5, 2029. The New Money Term Loans bear interest in cash, at the Borrower’s election from time to time, at either (i) Adjusted Term SOFR plus 5.50% per annum or (ii) ABR plus 4.50% per annum. The Roll-Up Term Loans bear interest and have payment and prepayment terms substantially consistent with the Class A Loans.

Additionally, the New Money Term Loans are subject to (i) a 2.00x multiple-on-invested-capital (“MOIC”), payable in cash upon partial or full repayment, prepayment, maturity or (ii) acceleration of the New Money Term Loans. The MOIC steps down to 1.75x

for repayments occurring on or after January 1, 2026 but prior to April 1, 2027 and to 1.50x for repayments occurring on or after the closing date of the Superpriority Facility and prior to January 1, 2026. The MOIC payable is accrued over the term of the New Money Term Loans using the effective interest method. As of September 30, 2025, the Company recorded a liability of $1.1 million related to the MOIC payable which is recorded in “Long-term debt, net of current portion” on the Condensed Consolidated Balance Sheets and included in the outstanding principal balance of the New Money Term Loans.

Pursuant to Amendment No. 14 and the Superpriority Credit Agreement, the Company recognized an aggregate loss on extinguishment of debt of $1.7 million. The Company recorded debt discounts of $25.1 million related to the Class A common stock issued as non-cash consideration pursuant to Amendment No. 14 and $2.4 million of closing fees payable in-kind, and thus capitalized and added to the outstanding principal balance. The Company paid an additional $8.0 million in debt issuance costs. The total debt discount and debt issuance costs are being amortized over the life of the debt to interest expense using the effective interest method.

As of September 30, 2025, the Borrower had a principal amount of $43.5 million and $35.0 million outstanding under the New Money Term Loans and Roll-Up Term Loans, respectively. The effective interest rates of the New Money Term Loans and Roll-Up Term Loans as of September 30, 2025 were 25.6% and 9.8%, respectively.

Blizzard Midco, LLC, the Borrower and certain other subsidiaries of the Company are guarantors of the Borrower’s obligations under the Existing Credit Agreement. In addition, the obligations of the Borrower are secured by a first priority lien on substantially all of such guarantors’ assets, including a pledge of all of the equity interests of each of their respective subsidiaries, in each case, subject to customary exceptions and limitations.

All principal, interest, premium, fees and other obligations in respect of the Superpriority Term Loans are (i) jointly and severally guaranteed by the subsidiaries of the Company that guarantee the Existing Credit Agreement, and any future material subsidiaries that execute a joinder to the guaranty and related collateral agreements and (ii) secured by a first priority lien on substantially all of the Borrower’s and the guarantors’ assets, subject to certain customary exceptions, on a senior basis to, and with payment priority senior to, all obligations outstanding under the Existing Credit Agreement on the closing date, subject to certain exceptions. In addition, pursuant to the Superpriority Credit Agreement, the Borrower is not permitted to make voluntary or mandatory prepayments of the Class A Revolving Loans and/or the Existing Term Loans, other than payment of amortization in respect of the Existing Term Loans, prior to the repayment in full, in cash, of the Superpriority Term Loan obligations.

The Existing Credit Agreement contains a number of covenants that, among other things and subject to certain exceptions, restrict the Borrower’s and its restricted subsidiaries’ ability to incur indebtedness; incur certain liens; consolidate, merge or sell or otherwise dispose of assets; make investments, loans, advances, guarantees and acquisitions; pay dividends or make other distributions on equity interests, or redeem, repurchase or retire equity interests; enter into transactions with affiliates; alter the business conducted by the Company and its subsidiaries; change their fiscal year; and amend or modify governing documents. In addition, the Existing Credit Agreement contains certain financial and non-financial covenants.

The Existing Credit Agreement also contains certain customary representations and warranties and affirmative covenants, and certain reporting obligations. In addition, the lenders under the Existing Credit Facilities are permitted to accelerate all outstanding borrowings and other obligations, terminate outstanding commitments and exercise other specified remedies upon the occurrence of certain events of default (subject to certain grace periods and exceptions), which include, among other things, payment defaults, breaches of representations and warranties, covenant defaults, certain cross-defaults and cross-accelerations to other indebtedness, certain events of bankruptcy and insolvency, certain judgments and changes of control. Subject to certain limited exceptions, substantially all of the Company’s assets are restricted from distribution.

Pursuant to the Superpriority Credit Agreement, the Borrower will be required to comply with a minimum liquidity covenant of (i)

$5.0 million at the end of each calendar week, commencing with the calendar week beginning October 5, 2025, (ii) $15.0 million at the end of each calendar week, commencing with the calendar week beginning March 29, 2026, (iii) $20.0 million at the end of each calendar week, commencing with the calendar week beginning June 28, 2026, and (iv) $30.0 million at the end of each calendar week, commencing with the calendar week beginning September 27, 2026 and thereafter; provided, that during any

period ending during the fiscal year ending December 31, 2026 and thereafter where the last business day of any calendar week therein occurs during the month of October, November or December, minimum liquidity shall instead be $10.0 million.

The Superpriority Credit Agreement contains customary non-financial covenants consistent with the Existing Credit Agreement that limit, among other things, mergers and acquisitions; investments, loans, and advances; affiliate transactions; changes to capital structure and the business; additional indebtedness; additional liens; the payment of dividends; and the sale of assets, in each case, subject to certain customary exceptions. In addition, the Superpriority Credit Agreement contains a covenant pursuant to which the Borrower and its subsidiaries are restricted from pursuing certain “liability management transactions” without the consent of the lenders holding a majority of the Roll-Up Term Loans and also includes certain restrictions on future financings.

The Superpriority Credit Agreement also contains customary events of default, including payment defaults, breaches of representations and warranties, covenant defaults, defaults under other material debt, events of bankruptcy and insolvency, failure of any guaranty or security document to be in full force and effect, and a change of control of the business.

In connection with the Company’s IPO in July 2020, the Company’s board of directors (the “Board of Directors”) approved an amended and restated certificate of incorporation and amended and restated bylaws. The amended and restated certificate of incorporation authorizes the issuance of up to 1,100,000,000 shares of Class A common stock, 690,000,000 shares of Class B common stock and 20,000,000 shares of preferred stock, each having a par value of $0.0001 per share. The number of shares of Class B common stock authorized is reduced for redemptions and forfeitures as they occur.

The Company’s amended and restated certificate of incorporation and the GHH, LLC Agreement require the Company and GHH, LLC at all times to maintain a one-to-one ratio between the number of shares of Class A common stock issued by the Company and the number of LLC Interests owned by the Company, except as otherwise determined by the Company. Additionally, the Company’s amended and restated certificate of incorporation and the GHH, LLC Agreement require that the Company and GHH, LLC at all times maintain a one-to-one ratio between the number of shares of Class B common stock owned by the Continuing Equity Owners and their respective permitted transferees and the number of LLC Interests owned by the Continuing Equity Owners and their respective permitted transferees, except as otherwise determined by the Company. Only the Continuing Equity Owners and the permitted transferees of Class B common stock are permitted to hold shares of Class B common stock. Shares of Class B common stock are transferable for shares of Class A common stock only together with an equal number of LLC Interests.

Holders of shares of the Company’s Class A common stock are entitled to one vote for each share held of record on all matters submitted to a vote of stockholders. Each share of Class B common stock entitles its holders to one vote per share on all matters presented to the Company’s stockholders generally. Holders of shares of Class B common stock will vote together with holders of the Company’s Class A common stock as a single class on all matters presented to the Company’s stockholders for their vote or approval, except for certain amendments to the Company’s amended and restated certificate of incorporation or as otherwise required by applicable law or the amended and restated certificate of incorporation. Holders of the Class B common stock are not entitled to participate in any dividends declared by the Board of Directors. Under the terms of the Company’s amended and restated certificate of incorporation, the Board of Directors is authorized to direct the Company to issue shares of preferred stock in one or more series without stockholder approval. The Board of Directors has the discretion to determine the rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, of each series of preferred stock.

The Continuing Equity Owners may, subject to certain exceptions, from time to time at each of their options require GHH, LLC to redeem all or a portion of their LLC Interests in exchange for, at the Company’s election (determined by at least two of the Company’s independent directors who are disinterested), newly-issued shares of Class A common stock on a one-for-one basis, or to the extent there is cash available from a secondary offering, a cash payment equal to a volume weighted average market price of one share of the Company’s Class A common stock for each LLC Interest so redeemed, in each case, in accordance with the terms of the GHH, LLC Agreement.

The weighted average ownership percentages for the applicable reporting periods are used to attribute net income (loss) and other comprehensive income (loss) to the Company and the non-controlling interest holders. Non-controlling interest represents the economic interest in GHH, LLC held directly or indirectly by the Continuing Equity Owners. The non-controlling interest holders' weighted average ownership percentages for the three and nine months ended September 30, 2025 were 47.2% and 51.5%, respectively. The non-controlling interest holders' weighted average ownership percentages for the three and nine months ended September 30, 2024 were 55.9% and 56.3%, respectively.

Upon the Company’s dissolution or liquidation, after payment in full of all amounts required to be paid to creditors and to the holders of preferred stock having liquidation preferences, if any, holders of Class A common stock and Class B common stock will be entitled to receive ratable portions of the Company’s remaining assets available for distribution; provided, that the holders of Class B common stock shall not be entitled to receive more than $0.0001 per share of Class B common stock and upon

receiving such amount, shall not be entitled to receive any of the Company’s other assets or funds with respect to such shares of Class B common stock.

On September 23, 2022 (the “Closing Date”), the Company issued 50,000 shares of the Company’s Series A Convertible Perpetual Preferred Stock (the “Issuance”), par value $0.0001 per share (the “Series A redeemable convertible preferred stock”), to Anthem Insurance Companies, Inc. and GH 22 Holdings, Inc. (the “Purchasers”) for an aggregate purchase price of $50.0 million, at $1,000 per share of the Series A redeemable convertible preferred stock.

The Company is authorized to issue 20,000,000 shares of preferred stock with a par value of $0.0001 per share as of both September 30, 2025 and December 31, 2024, which had not been designated to any specific classes of preferred stock prior to the Closing Date. On the Closing Date, the Company designated and authorized the issuance of 50,000 shares under the Series A redeemable convertible preferred stock and 200,000 shares under the Series A-1 Convertible Non-Voting Perpetual Preferred Stock (the “Series A-1 convertible preferred stock”).

The Series A redeemable convertible preferred stock ranks senior to the shares of the Company’s Class A common stock and Class B common stock with respect to dividend rights and rights on the distribution of assets on any voluntary or involuntary liquidation, dissolution or winding up of the affairs of the Company. The Series A redeemable convertible preferred stock has an initial liquidation preference of $1,000 per share, which shall increase by accumulated quarterly dividends that are not paid in cash (“compounded dividends”). Dividends on each share of Series A redeemable convertible preferred stock shall accrue at an annual rate equal to 7.0%. Holders of Series A-1 convertible preferred stock are only entitled to dividends if the Company declares such dividends. For the three and nine months ended September 30, 2025, the Company accrued $1.0 million and $2.9 million, respectively, of dividends relating to the Series A redeemable convertible preferred stock that were not paid in cash. For the three and nine months ended September 30, 2024, the Company accrued $0.9 million and $2.7 million, respectively, of dividends relating to the Series A redeemable convertible preferred stock that were not paid in cash. The accrued dividends are included in temporary equity on the Condensed Consolidated Balance Sheets.

The Series A redeemable convertible preferred stock is convertible in full at the option of the holders into the number of shares of Class A common stock equal to the quotient of (a) the sum of (i) the liquidation preference (reflecting increases for compounded dividends) plus (ii) the accrued dividends with respect to each share of convertible preferred stock as of the applicable conversion date divided by (b) the conversion price ($9.60 as of September 30, 2025 and subject to adjustment based on certain changes to the Company’s Class A common stock) as of the applicable conversion date. Notwithstanding the foregoing, a holder of Series A redeemable convertible preferred stock may elect to receive upon conversion, in lieu of the shares of Class A common stock otherwise deliverable, one share of Series A-1 convertible preferred stock for every 1,000 shares of Class A common stock otherwise deliverable upon conversion. The Series A-1 convertible preferred stock will be essentially a substitute for the Class A common stock in the form of non-voting preferred stock.

The terms of the Series A redeemable convertible preferred stock and Series A-1 convertible preferred stock contain certain anti-dilution adjustments. Subject to certain conditions, at any time after the third anniversary of the Closing Date, if the volume weighted average price per share of Class A common stock on The Nasdaq Global Market is equal to or greater than 150.0% of the then-applicable conversion price for each of at least twenty (20) trading days, whether or not consecutive, in any period of thirty (30) consecutive trading days ending on and including the trading day immediately before the Company provides the holders with notice of its election to convert all or a portion of the Series A redeemable convertible preferred stock into the relevant number of shares of Class A common stock or Series A-1 convertible preferred stock (at the election of the holder), the Company may elect to convert all or a portion of the Series A redeemable convertible preferred stock into the relevant number of shares of Class A common stock or Series A-1 convertible preferred stock.

In the event of any voluntary or involuntary liquidation, dissolution or winding up of the affairs of the Company, the holders of shares of Series A-1 convertible preferred stock (if issued upon conversion of the Series A redeemable convertible preferred stock) will be entitled, out of assets legally available therefor, and subject to the rights of the holders of any senior stock (including the Series A redeemable convertible preferred stock) or parity stock (including the Class A and Class B common stock) and the rights of the Company’s existing and future creditors, to receive an aggregate amount per share equal to 1,000 (as may be adjusted) times the aggregate amount to be distributed per share to holders of shares of Class A common stock. Each holder of a whole share of Series A-1 convertible preferred stock (if issued upon conversion of the Series A redeemable convertible preferred stock) shall be entitled to receive when, as and if declared by the Board of Directors out of funds legally available for the purpose, an amount per share equal to 1,000 (as may be adjusted) times the aggregate per share amount of all cash dividends, and 1,000 (as may be adjusted) times the aggregate per share amount (payable in kind) of all non-cash dividends or other distributions other than a dividend payable in shares of Class A common stock or a subdivision of the outstanding shares of Class A common stock (by reclassification or otherwise), declared on each share of Class A common stock since the first issuance of any share of Series A-1 convertible preferred stock. Each holder of Series A-1 convertible preferred stock (if issued upon conversion of the Series A redeemable convertible preferred stock) will have the right, at such holder’s option, to convert in full each share of such holder’s Series A-1 convertible preferred stock at such time into the number of shares of Class A common

stock based upon a conversion ratio of 1,000 shares of Class A common stock for each share of Series A-1 convertible preferred stock (such ratio being subject to adjustment).

Under the Certificate of Designations, holders of the Series A redeemable convertible preferred stock are entitled to vote with the holders of the Class A common stock on an as-converted basis on all matters submitted to a vote of the holders of the Class A common stock. Notwithstanding the foregoing: (1) the lead Purchaser’s voting rights shall not exceed 9.99% of the voting rights associated with the issued and outstanding shares of capital stock of the Company at any time; and (2) the voting rights of the Purchasers holding Series A redeemable convertible preferred stock, voting on an as-converted basis with the holders of the Class A common stock and the holders of any other class or series of capital stock of the Company then entitled to vote, shall be capped at the maximum amount that would not result in requiring stockholder approval for the exercise of such voting rights pursuant to the listing rules of The Nasdaq Global Market. The Series A-1 convertible preferred stock is not entitled to vote with the Class A common stock on matters submitted to a vote of the holders of the Class A common stock and will have no voting rights except as required by applicable law.

In addition, holders of the preferred stock are entitled to a separate class vote with respect to, among other things, amendments to the Company’s organizational documents that materially, adversely and disproportionately affect the Series A redeemable convertible preferred stock, authorizations or issuances by the Company of securities that are senior to or pari passu with the Series A redeemable convertible preferred stock and issuing any debt security (for the avoidance of doubt, excluding any draws under the Company’s Existing Credit Agreement referenced in the Certificate of Designations), if the Company’s Consolidated Total Net Debt (as defined in the Certificate of Designations) following such action would exceed four times the Company’s Consolidated EBITDA (as defined in the Certificate of Designations) for the Company’s most recently completed four consecutive fiscal quarters.

At any time following the fifth anniversary of the Closing Date, the Company may redeem the Series A redeemable convertible preferred stock, in whole or in part, for a per share amount in cash equal to the liquidation preference (reflecting increases for compounded dividends) thereof plus all accrued dividends as of the applicable redemption date. Upon certain change of control events involving the Company, (i) a holder of the Series A redeemable convertible preferred stock may, so long as such payment would not otherwise result in a breach of, or event of default under, then-existing credit agreements, indentures or other financing arrangements, require the Company to purchase and (ii) subject to a holder’s right to convert its shares of Series A redeemable convertible preferred stock into Class A common stock or Series A-1 convertible preferred stock at the then-current conversion price, the Company may elect to purchase, all or a portion of such holder’s shares of Series A redeemable convertible preferred stock that have not been so converted, in each case at a purchase price per share of Series A redeemable convertible preferred stock, payable in cash, equal to (i) if the change of control effective date occurs at any time prior to the fifth anniversary of the Closing Date, 160.0% of a Purchaser’s original investment amount and (ii) if the change of control effective date occurs on or after the fifth anniversary of the Closing Date, the liquidation preference (reflecting increases for compounded dividends) of such share of Series A redeemable convertible preferred stock plus the accrued dividends in respect of such share of Series A redeemable convertible preferred stock as of the change of control purchase date.

The Purchasers have entered into a customary registration rights agreement with respect to shares of Class A common stock held by the Purchasers issued upon any future conversion of the Series A redeemable convertible preferred stock or Series A-1 convertible preferred stock.

In connection with the Issuance, the Company, as the managing member of GHH, LLC, caused GHH, LLC (i) to issue to the Company, in exchange for the proceeds from the Issuance, Series A preferred units and (ii) to authorize another series of preferred units, in each case having an aggregate liquidation preference and having terms substantially economically equivalent to the aggregate liquidation preference and the economic terms of the Series A redeemable convertible preferred stock and the Series A-1 convertible preferred stock, respectively, and entered into Amendment No. 2 to the GHH, LLC Agreement to effectuate the same.

The Company classifies the Series A redeemable convertible preferred stock and Series A-1 convertible preferred stock outside of permanent equity as temporary equity since the redemption of such shares is not solely within the Company’s control. The Company does not remeasure the redeemable convertible preferred stock because it is not currently redeemable and not probable of becoming redeemable. The redeemable convertible preferred stock was recorded at fair value upon issuance, net of issuance costs of $1.6 million.

As consideration for, and as a condition to, the lenders’ entry into Amendment No. 14 to the Existing Credit Agreement, on August 6, 2025, the Company issued to lenders (or their affiliates) holding Class A Revolving Loans and Existing Term Loans (for these purposes, the “Subscribers”), pro rata based on their respective holdings thereof, an aggregate of 4,766,219 shares of Class A common stock, which represented an aggregate of 19.99% of the total issued and outstanding shares of the Company’s Class A common stock and Class B common stock, calculated immediately prior to the consummation of the transactions contemplated by Amendment No. 14, or 16.66% post-closing. Pursuant to a Registration Rights Agreement among the Company and the Subscribers (as amended), the Subscribers are entitled to certain customary registration rights with respect to the shares issued to them. Refer to Note 4, “Long-Term Debt” for more information.

The following table summarizes share-based compensation expense (benefit) by operating function for the periods presented:

(1)For the three and nine months ended September 30, 2025 and 2024, share-based compensation expense (benefit) includes expense related to the stock appreciation rights (“SARs”), which are liability classified awards.

Basic income (loss) per share is computed by dividing net income (loss) attributable to common stockholders by the weighted-average number of shares of Class A common stock outstanding during the period. Diluted income (loss) per share is computed giving effect to all potentially dilutive shares.

A reconciliation of the numerator and denominator used in the calculation of basic and diluted net income (loss) per share of Class A common stock is as follows:

The following number of shares were excluded from the calculation of diluted income (loss) per share of Class A common stock because the effect of including such potentially dilutive shares would have been antidilutive:

Shares of Class B common stock do not share in earnings and are not participating securities. Accordingly, separate presentation of income (loss) per share of Class B common stock under the two-class method has not been presented. Shares

of Series A redeemable convertible preferred stock are not participating securities as holders receive a contractual dividend. Accordingly, separate presentation of income (loss) per share of Series A redeemable convertible preferred stock under the two-class method has not been presented.

The Company is taxed as a corporation for income tax purposes and is subject to federal, state and local taxes on the income allocated to it from GHH, LLC based upon the Company’s economic interest in GHH, LLC. The Company is the sole managing member of GHH, LLC and, as a result, consolidates the financial results of GHH, LLC. GHH, LLC is a limited liability company taxed as a partnership for income tax purposes except for a foreign subsidiary, which is treated as a foreign disregarded entity. As a partnership, GHH, LLC does not pay any federal income taxes, as income or loss is included in the tax returns of the individual members. In 2024, the Company acquired a 100% equity interest in e-TeleQuote Insurance, Inc. (“e-TeleQuote”) which is taxed as a corporation. These corporations are subject to federal and state income taxes in the jurisdictions in which they operate. Additionally, the Company’s foreign subsidiaries are subject to foreign income taxes in the jurisdiction in which they operate. The accruals for such taxes are included in the Condensed Consolidated Financial Statements.

The Company’s effective tax rate for the three and nine months ended September 30, 2025 was 0.2% and (0.1)%, respectively. The Company’s effective tax rate for the three and nine months ended September 30, 2024 was (0.1)% and 0.2%, respectively. The effective tax rate for each period is lower than the statutory tax rate primarily due to the effect of loss entities for which the Company excludes from its annual effective tax rate calculation and loss attributable to non-controlling interests.

In connection with the IPO, the Company entered into a Tax Receivable Agreement with GHH, LLC, the Continuing Equity Owners and the Blocker Shareholders that will provide for the payment by the Company to the Continuing Equity Owners and the Blocker Shareholders of 85% of the amount of tax benefits, if any, that the Company actually realizes (or in some circumstances is deemed to realize). The amounts payable under the Tax Receivable Agreement will vary depending upon a number of factors, including the amount, character and timing of the taxable income of the Company in the future. As of both September 30, 2025 and December 31, 2024 the liability related to the Tax Receivable Agreement was $1.1 million. Should the Company determine that any additional Tax Receivable Agreement liability is considered probable at a future date based on new information, any changes will be recorded within earnings at that time.

The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers. The primary services provided by the Company relate to the sale and administration of Medicare insurance products through either the agency model or the non-agency model, as described below. Beginning in the quarter ended June 30, 2025, we revised the presentation of disaggregation of revenue to further disaggregate Other Revenue into other agency revenue and other non-agency revenue. Prior period presentation has been conformed to reflect current period presentation.

The table below depicts the disaggregation of revenue and is consistent with how the Company evaluates its financial performance:

(1)Commission revenue excludes commissions generated from the sale of individual and family plan insurance products.

Medicare agency revenue refers to the commission revenue and partner marketing and other revenue the Company receives when GoHealth agents or the Company’s independent network of outsourced agents, also referred to as external agents, enroll the consumer and submit the Medicare policy application to the health plan partner, becoming the agent of record. The Company records as commission revenue the expected amount of initial commissions received from the health plan partners and any renewal commissions to be paid on such placement as long as the policyholder remains with the same insurance product, also known as the total estimated LTV of the policy, net of an estimated constraint. The consideration is variable based on the estimated amount of time a policy will remain in force, which is based on historical experience or health plan partner experience to the extent available, industry data and expectations as to future retention rates. Additionally, the Company considers the application of a constraint and only recognizes the amount of variable consideration that it believes is probable that it will be entitled to receive and will not be subject to a significant revenue reversal in the future. The Company monitors and updates this estimate at each reporting date.

The Company utilizes a practical expedient to estimate commission revenue for each insurance product by applying the use of a portfolio approach to group approved members by the effective month of the relevant policy (referred to as a “vintage”). On a quarterly basis, the Company re-estimates LTV at a vintage level for outstanding vintages, which takes into account cash received as compared to the original estimates and reviews and monitors changes in the data used to estimate LTV. Changes in LTV may result in an increase or a decrease to revenue and a corresponding change to commissions receivable. The Company analyzes these differences and to the extent the Company believes differences in the estimates are indicative of a change to prior period LTVs, the Company will adjust revenue for the affected vintages at the time such determination is made and when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur.

The Company is also compensated by its health plan partners for providing Medicare-related marketing services over a predetermined measurement period, which the Company records as partner marketing and other revenue. The Company recognizes these revenues over the measurement period as insurance applications produced by the Company are generated. The Company generally gets paid a fixed fee per application, with the amount of variable consideration resolved within 90 days of the application.

Non-agency revenue refers to services provided by the Company that support enrollment and engagement activities in which the Company is not the agent of record. The non-agency model moves away from the agency structure in that cash is collected in advance or in close proximity to the point in time revenue is recognized. Medicare non-agency revenue includes enrollment and engagement services through Encompass Connect and Encompass Engage. Encompass Connect is designed to provide enrollment related services to participating partners for Medicare products. The Company is compensated for generating and transferring leads to the health plan partners, at which time the health plan partner representative will enroll and submit the application, becoming the agent of record. Revenue is recognized at the point in time the lead is transferred. The Company’s performance obligation is complete when a health plan partner has received a lead, with the amount of variable consideration generally resolved within 90 days of when the related policy effectuates. The Company estimates the amount of variable consideration that it expects to receive based on historical experience with commission revenue or health plan partner experience to the extent available and expectations as to future retention rates. The Company does not receive commissions or fees on subsequent renewals generated from the transferred leads. Encompass Engage includes post-enrollment member outreach and engagement services, including facilitating an onboarding experience customized to a members’ Medicare plan and health needs. The Company recognizes Encompass Engage revenue at the point in time the service is provided based on member retention and providing post-enrollment services.

Medicare non-agency revenue also includes value-based care provider engagement, health risk assessments, social determinants of health screening and preferred pharmacy programs. The Company recognizes revenue for the related performance obligation at the point in time the service is provided.

Other non-agency revenue includes enrollment related services through GoHealth Protect, a suite of products to cover unexpected life events, including guaranteed acceptance life insurance. The Company is compensated for guaranteed acceptance life insurance through the non-agency model where GoHealth is not the agent of record and cash is collected in close proximity to the point of sale. Revenue is recognized at the point in time the enrollment is submitted, approved by the health plan partner, and for which the payment information was received by the health plan partner. The Company’s performance obligation is complete when the health plan partner has received the enrollment. The Company estimates the amount of variable consideration that it expects to receive based on expectations as to future retention rates and average premium levels. Other non-agency revenue also includes revenue unrelated to Medicare products, including certain post-enrollment services.

Other agency revenue is comprised of revenue unrelated to Medicare products, including commissions revenue generated from the sale of individual and family plan insurance products.

The Company records commissions receivable, commissions payable and deferred revenue related to its contracts with customers. Commissions receivable represents estimated variable consideration for commissions to be received from health plan partners for performance obligations that have been satisfied. Commissions payable represents estimated commissions to be paid to the Company’s external partners.

The Company had unbilled receivables for performance-based enrollment fees and non-agency revenue, as well as prepaid expenses for revenue share, as of September 30, 2025 and December 31, 2024 of $4.2 million and $20.9 million, respectively, which are recorded in prepaid expenses and other current assets on the Condensed Consolidated Balance Sheets. The $16.7 million decrease was primarily due to a decline in unbilled receivables for performance-based enrollment fees pursuant to Encompass Connect. In addition, the Company had accrued payments for revenue share as of September 30, 2025 and December 31, 2024 of $19.8 million and $29.8 million, respectively, which are recorded in accrued liabilities on the Condensed Consolidated Balance Sheets.

Deferred revenue includes amounts collected for partner marketing services and non-agency revenue in advance of the Company satisfying its performance obligations for such customers. The decrease in deferred revenue during the nine months ended September 30, 2025 compared to December 31, 2024 was primarily due to less cash received as of September 30, 2025 compared to December 31, 2024 for marketing, administrative and enrollment fees in advance of performing such services that the Company expects to satisfy within the next twelve months. During the three months ended September 30, 2025 and 2024, the Company recognized revenue that was recorded in deferred revenue on the Condensed Consolidated Balance Sheets at the beginning of the respective fiscal year of $2.1 million and $7.6 million, respectively. During the nine months ended September 30, 2025 and 2024, the Company recognized revenue that was recorded in deferred revenue on the Condensed Consolidated Balance Sheets at the beginning of the respective fiscal year of $49.0 million and $51.1 million, respectively.

Commissions receivable activity is summarized as follows:

(1)Commission revenue includes commissions generated from the sale of individual and family plan insurance products.

The Company’s contracts with health plan partners expose it to credit risk because a financial loss could be incurred if the counterparty does not fulfill its financial obligation. While the Company is exposed to credit losses due to the potential non-performance of its counterparties, the Company considers this risk to be remote. The Company estimates the allowance for credit losses using available information from internal and external sources related to historical experiences, current conditions and forecasts. Estimates of loss are determined by using historical collections data as well as historical information obtained through research and review of other peer companies. The estimated exposure of default is determined by applying these internal and external factors to the commissions receivable balances. The Company estimates the maximum credit risk in determining the commissions receivable amount recorded on the Condensed Consolidated Balance Sheets.

The following table presents health plan partners representing 10% or more of the Company’s total net revenues for the periods indicated:

The Company does not require collateral or other security in granting credit. As of September 30, 2025, one customer represented 10% or more of the Company’s total accounts receivable and unbilled receivables and, in aggregate, represented 91.5%, or $1.6 million, of the combined total. As of December 31, 2024, two customers each represented 10% or more of the Company’s total accounts receivable and unbilled receivables and, in aggregate, represented 74.6%, or $17.6 million, of the combined total.

The Company has entered into operating agreements with lease periods expiring between 2025 and 2032. Lease expense for operating lease payments is recognized on a straight-line basis over the lease term.

Components of lease expense are as follows, all recorded within operating expenses in the Condensed Consolidated Statements of Operations:

(1)Includes costs related to leases, which at the commencement date, have a lease term of 12 months or less.

(2)Includes costs incurred by the Company for the right to use an underlying asset that vary because of changes in facts or circumstances occurring after the commencement date, other than the passage of time.

As part of the Company’s continued cost savings initiatives, the Company is actively looking to terminate or sublease certain office spaces and call centers. These actions resulted in $4.5 million in operating lease impairment charges for the three months ended September 30, 2025 and $5.3 million in operating lease impairment charges for the nine months ended September 30, 2025 which are recorded in “Indefinite and long-lived asset impairment charges” on the Condensed Consolidated Statements of Operations. There were no operating lease impairment charges for the three and nine months ended September 30, 2024. The operating lease impairment charges reduce the carrying value of the associated ROU assets and leasehold improvements to their estimated fair values. For the nine months ended September 30, 2025, the Company recognized $0.3 million of one-time gains from the remeasurement of the lease liability and adjustment of the ROU asset (which was previously impaired) related to the early termination of two of its leases during the first half of the fiscal year. The gain on lease remeasurement was recorded in general and administrative expense on the Condensed Consolidated Statements of Operations. Refer to Note 2, “Fair Value Measurements” for further details.

As of September 30, 2025, future minimum lease payments for operating leases consisted of the following: